ITOLIZUMAB (monoclonal antybody) Chemical Properties

form 

Liquid

color 

Colorless to light yellow

ITOLIZUMAB (monoclonal antybody) Usage And Synthesis

Uses

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

in vivo

References

[1] Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. DOI:10.1186/s12979-020-00207-8
[2] Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. DOI:10.1080/14712598.2020.1798399
[3] Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. DOI:10.4103/ijd.IJD_467_16
[4] Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. DOI:10.1016/j.ebiom.2019.08.008
[5] Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688. DOI:10.1038/s41467-022-31229-z
[6] Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088. DOI:10.1371/journal.pone.0180088
[7] Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.

ITOLIZUMAB (monoclonal antybody)(1116433-11-4)Related Product Information

• Netakimab
• Sifalimumab
• VEGFR2 Kinase Inhibitor I
• Racotumomab
• Fletikumab
• Landogrozumab
• Blosozumab
• Alirocumab
• Romosozumab
• Ozanezumab